Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...
Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...
NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...
Pfizer says COVID vaccine protection lasts at least 6 months; Company can now seek full FDA approval
The ongoing Phase 3 clinical trial of Pfizer/BioNTech's coronavirus vaccine confirms its protection lasts at least six months after the second dose, the companies said Thursday. The companies can now ...
PHILADELPHIA -- To help fend off another wave of Covid-19, people will need a fourth dose of vaccine, Pfizer CEO Albert Bourla said Sunday. "Many variants are coming, and Omicron was the first one ...
Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE , more than five years after both ...
Vaccine advisers to the US Food and Drug Administration voted 17-0 with one abstention Tuesday to recommend Pfizer's COVID-19 vaccine in children 5 to 11. Members of the FDA's Vaccines and Related ...
LOS ANGELES -- The COVID-19 vaccines made by Pfizer and Moderna both require two doses to be administered, several weeks apart, for them to be fully effective. But there has been some scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback